Background {#Sec1}
==========

Ulcerative colitis (UC), as the most common form of inflammatory bowel disease (IBD), is a form of colitis that includes characteristic ulcers, or open sores \[[@CR1]\]. Ulcerative colitis has an incidence of 1 to 20 cases per 100,000 individuals per year, and a prevalence of 8 to 246 per 100,000 individuals \[[@CR2]\]. Patients with UC have an increased risk of developing colorectal cancer \[[@CR3]\]. The pathogenesis of UC is not well defined, but it is proposed that genetic and environmental factors result in an aberrant immune response to a subset of commensal enteric bacteria \[[@CR4],[@CR5]\]. Recent genome-wide association (GWA) studies and meta-analyses have identified many single-nucleotide polymorphisms (SNPs) associated with UC \[[@CR6],[@CR7]\].

Interleukin-22 (*IL-22*) is a member of the *IL-10* family of anti-inflammatory cytokines that mediates epithelial immunity \[[@CR8]\]. *IL-22* is synthesized by different cell types including T- and NK-cells, and has been reported to mediate the crosstalk between inflammatory cells and keratinocytes \[[@CR9]-[@CR11]\]. *IL-22* expression was induced in several human inflammatory conditions, including IBD \[[@CR12],[@CR13]\]. *IL-22* expression was found to be increased in patients with UC \[[@CR14]\]. Several SNPs have previously been identified in the *IL-22* gene \[[@CR15]-[@CR22]\].

Whether genetic polymorphisms of *IL-22* also influence UC risk is still unknown. The aim of this study was to investigate the association between the *IL-22* gene polymorphisms (−429 C/T, +1046 T/A and +1995 A/C) and the risk of UC in Chinese Han patients.

Methods {#Sec2}
=======

Study subjects {#Sec3}
--------------

This hospital-based case--control study comprised 180 patients with UC and 180 age- and gender-matched controls during the years 2009 to 2014. Diagnosis of UC was based on clinical, radiological, endoscopic and histological examinations \[[@CR23]\]. To confirm the diagnosis, two physicians reviewed the hospital records and validated each case. The location of disease was defined according to the Montreal classification (ulcerative proctitis, left-sided colitis, and extensive colitis) \[[@CR24]\]. The severity of UC was determined according to Truelove and Witts criteria (mild colitis, moderate colitis, and severe colitis) \[[@CR25]\]. According to their clinical courses, UC cases were classified into one episode, relapsing and continuous phenotypes \[[@CR26]\]. The control group was composed of age- and gender-matched subjects who had undergone an endoscopic examinations in the same recruitment period as the UC patients, without evidence of UC. In addition, similar to the cases the controls were all required to be born in China to native Chinese Han parents. Informed consent was obtained from all subjects after a full explanation of the project according to the Declaration of Helsinki, and the specimen collecting procedures were approved by the Institutional Ethical Committee of Guangdong Medical College.

Genotyping {#Sec4}
----------

Whole blood (3--6 ml) was obtained by venepuncture using standard EDTA collection tubes. DNA was extracted using the QIAGEN Gentra Puregene blood kit (QIAGEN Inc., Valencia, CA, USA). Genotypes of 3 common polymorphisms of the *IL-22* gene were determined by fluorogenic 5′ exonuclease assays (TaqMan). Primer and probe sequences for 5′-exonuclease assays for *IL-22* polymorphisms were listed in Table [1](#Tab1){ref-type="table"}. The polymerase chain reaction (PCR) was performed in a Primus 96 plus thermal cycler using a total volume of 5 μl containing 2.5 μl of Universal-MasterMix, 0.125 μl 40x Assay-by- Design mix, 0.375 μl H~2~O and 2 μl DNA. Reactions were overlaid with 15 μl of mineral oil. Cycling parameters were: 10 min at 94°C for primary denaturation, followed by 40 cycles of 20 s at 92°C and 1 min at 60°C. Fluorescence was measured in a lambda Fluoro 320 Plus plate reader (MWG Biotech AG, Germany).Table 1**Primer and probe sequences for 5′-exonuclease assays for** ***IL-22*** **polymorphismsSNPsrs2227485rs1182844rs1179246**Exchange−429 C/T+1046 T/A+1995 A/CForward PrimerAAAATGAGTCCGTGACCAAAATGCCCACCTATGAGACTTCCCTATCAGTGAAAAAGCCTTCCTGCCTAATGGReverse PrimerACACAATTGTTTTGTCTTAGTAGAGTTCAGATCACTAAAGGAAAAGGAAAGCTGTGTTTGGTGCTGCCTAAAGGTCAGAWildtype-ProbeFAM-CTCCTATAGTGACTGAGTAA-NFQVIC-AAACTTACTAGTAGGTATGACTC-NFQVIC-TGAACAGAGTTATCTGCCTC-NFQMutant-ProbeVIC-CTCCTATAGTGGCTGAGTAA-NFQFAM-CTTACTAGTAGGAATGACTC-NFQFAM-AACAGAGTTAGCTGCCTC-NFQAbbreviations: *SNP* single nucleotide polymorphisms.

Statistical analysis {#Sec5}
--------------------

STATA program version 11.0 (StataCorp LP, TX) was used for statistical analyses. Continuous variables were analysed by *t*-test and presented as mean ± standard deviation (SD). Categorical variables are presented as percentages and were compared by chi-squared test. Odds ratio (OR) and 95% confidence intervals (CI) were determined by logistic regression analysis. For a new work, we also use the Bonferroni correction for total number of independent comparisons. The Hardy-Weinberg equilibrium was tested for goodness-of-fit chi-square test with one degree of freedom to compare the observed genotype frequencies among the subjects with the expected genotype frequencies. The *P*-value less than 0.05 was considered statistically significant.

Results {#Sec6}
=======

Characteristics of participants {#Sec7}
-------------------------------

Demographic and clinical characteristics of study participants were showed in Table [2](#Tab2){ref-type="table"}. No significant differences were found between the UC cases and controls in age, sex, body mass index (BMI), smoking status and family history of inflammatory bowel disease (IBD) (Table [2](#Tab2){ref-type="table"}). The genotype were in agreement with the Hardy-Weinberg equilibrium.Table 2**Demographic and clinical characteristics of study participantsUCControls*P***Number of subjects180180Sex (Male/Female)95/8598/820.75Age (years, mean ± SD)39.7 ± 12.540.2 ± 13.10.71BMI (kg/m^2^, mean ± SD)20.2 ± 3.719.8 ± 3.50.29Smoking status (Ever/Never)79/10175/1050.67Family history of IBD (Positive/Negative)14/16611/1690.54Clinical type One episode16 Relapsing70 Continuous94Location Proctitis (E1)73 Left side (E2)64 Extensive (E3)43Disease severity Mild76 Moderate95 Severe9Abbreviations: *UC* ulcerative colitis, *BMI* body mass index, *IBD* inflammatory bowel disease.

***IL-22*** −429C/T polymorphisms and UC {#Sec8}
----------------------------------------

Patients with UC had a significantly higher frequency of *IL-22* −429 TT genotype (OR =2.43, 95% CI = 1.35, 4.37; *P* = 0.003) and −429 T allele (OR =1.54, 95% CI = 1.14, 2.07; *P* = 0.004) than controls (Table [3](#Tab3){ref-type="table"}). The findings are still emphatic by the Bonferroni correction. When stratifying by clinical type, location and disease severity of UC, no significant differences were found in any groups (Table [4](#Tab4){ref-type="table"}).Table 3**Genotype and allele frequencies of** ***IL-22*** **gene polymorphisms among ulcerative colitis cases and healthy controlsGenotypesUC (n = 150)Controls (n = 150)OR (95% CI)*P***−429 CC57(31.7)68(37.8)1.00(Reference)−429 CT70(38.9)86(47.8)0.97(0.61,1.56)0.90−429 TT53(29.4)26(14.4)2.43(1.35,4.37)0.003−429 C allele frequency184(51.1)222(61.7)1.00(Reference)−429 T allele frequency176(48.9)138(38.3)1.54(1.14,2.07)0.004+1046 TT88(48.9)94(52.2)1.00(Reference)+1046 TA63(35.0)61(33.9)1.10(0.70,1.74)0.67+1046 AA29(16.1)25(13.9)1.24(0.67,2.28)0.49+1046 T allele frequency239(66.4)249(69.2)1.00(Reference)+1046 A allele frequency121(33.6)111(30.8)1.14(0.83,1.55)0.43+1995 AA76(42.2)81(45.0)1.00(Reference)+1995 AC65(36.1)63(35.0)1.10(0.69,1.75)0.69+1995 CC39(21.7)36(20.0)1.16(0.67,2.00)0.61+1995 A allele frequency217(60.3)225(62.5)1.00(Reference)+1995 C allele frequency143(39.7)135(37.5)1.10(0.81,1.48)0.54Abbreviations: *UC* ulcerative colitis, *OR* odds ratio, *CI* confidence interval.Table 4**Stratification analysis of** ***IL-22***  **−429 C/T polymorphisms in ulcerative colitis casesCases (n = 180)CCCTTTn (%)OR (95% CI)*P*n (%)OR (95% CI)*P*n (%)OR (95% CI)*P***Clinical type18057(31.7)1(Reference)70(38.9)1(Reference)53(29.4)1(Reference)One episode165(31.2)0.99(0.35,2.81)0.987(43.8)1.13(0.44,2.85)0.804(25.0)0.85(0.27,2.65)0.78Relapsing7024(34.3)1.08(0.62,1.88)0.7826(37.1)0.96(0.56,1.62)0.8720(28.6)0.97(0.54,1.74)0.92Continuous9428(29.8)0.94(0.56,1.58)0.8237(39.4)1.01(0.63,1.62)0.9629(30.8)1.05(0.63,1.76)0.86Location18057(31.7)1(Reference)70(38.9)1(Reference)53(29.4)1(Reference)Proctitis (E1)7324(32.9)1.04(0.60,1.80)0.8927(37.0)0.95(0.57,1.60)0.8522(30.1)1.02(0.58,1.80)0.94Left side (E2)6420(31.3)0.99(0.55,1.77)0.9726(40.6)1.05(0.61,1.78)0.8718(28.1)0.96(0.52,1.75)0.88Extensive (E3)4313(30.2)0.96(0.48,1.90)0.8917(39.6)1.02(0.54,1.90)0.9613(30.2)1.03(0.51,2.05)0.94Disease severity18057(31.7)1(Reference)70(38.9)1(Reference)53(29.4)1(Reference)Mild7625(32.9)1.04(0.61,1.79)0.8928(36.8)0.95(0.57,1.58)0.8423(30.3)1.03(0.59,1.80)0.92Moderate9529(30.5)0.96(0.58,1.61)0.8938(40.0)1.03(0.65,1.64)0.9128(29.5)1.00(0.59,1.68)0.99Severe93(33.3)1.05(0.28,4.02)0.944(44.5)1.14(0.34,3.83)0.832(22.2)0.76(0.16,3.60)0.72Abbreviations: *OR* odds ratio, *CI* confidence interval.

***IL-22*** +1046 T/A polymorphisms and UC {#Sec9}
------------------------------------------

The *IL-22* +1046 T/A gene polymorphisms were not associated with a risk of UC (Table [3](#Tab3){ref-type="table"}). When stratifying by clinical type, location and disease severity of UC, no significant differences were found in any groups (Table [5](#Tab5){ref-type="table"}).Table 5**Stratification analysis of** ***IL-22***  **+ 1046 T/A polymorphisms in ulcerative colitis casesCases (n = 180)TTTAAAn (%)OR (95% CI)*P*n (%)OR (95% CI)*P*n (%)OR (95% CI)*P***Clinical type18088(48.9)1(Reference)63(35.0)1(Reference)29(16.1)1(Reference)One episode167(43.7)0.89(0.35,2.55)0.816(37.6)1.07(0.40,2.86)0.893(18.7)1.16(0.32,4.25)0.82Relapsing7033(47.1)0.96(0.59,1.57)0.8826(37.2)1.06(0.62,1.81)0.8311(15.7)0.98(0.46,2.06)0.95Continuous9448(51.1)1.04(0.68,1.61)0.8431(33.0)0.94(0.57,1.55)0.8215(15.9)0.99(0.51,1.94)0.98Location18088(48.9)1(Reference)63(35.0)1(Reference)29(16.1)1(Reference)Proctitis (E1)7337(50.7)1.04(0.65,1.66)0.8825(34.2)0.98(0.57,1.67)0.9411(15.1)0.94(0.44,1.97)0.86Left side (E2)6433(51.6)1.06(0.65,1.72)0.8321(32.8)0.94(0.53,1.66)0.8210(15.6)0.97(0.45,2.10)0.94Extensive (E3)4318(41.9)0.86(0.47,1.57)0.6217(39.5)1.13(0.60,2.12)0.708(18.6)1.16(0.49,2.70)0.74Disease severity18088(48.9)1(Reference)63(35.0)1(Reference)29(16.1)1(Reference)Mild7635(46.1)0.94(0.59,1.51)0.8128(36.8)1.05(0.63,1.77)0.8513(17.1)1.06(0.52,2.15)0.87Moderate9548(50.5)1.03(0.67,1.59)0.8832(33.7)0.96(0.59,1.58)0.8815(15.8)0.98(0.50,1.92)0.95Severe95(55.6)1.14(0.37,3.49)0.823(33.3)0.95(0.25,3.63)0.941(11.1)0.69(0.08,5.65)0.73Abbreviations: *OR* odds ratio, *CI* confidence interval.

***IL-22*** +1995 A/C polymorphisms and UC {#Sec10}
------------------------------------------

The *IL-22* +1995 A/C gene polymorphisms were not associated with a risk of UC (Table [3](#Tab3){ref-type="table"}). When stratifying by clinical type, location and disease severity of UC, no significant differences were found in any groups (Table [6](#Tab6){ref-type="table"}).Table 6**Stratification analysis of** ***IL-22***  **+1995 A/C polymorphisms in ulcerative colitis casesCases (n = 180)AAACCCn (%)OR (95% CI)*P*n (%)OR (95% CI)*P*n (%)OR (95% CI)*P***Clinical type18076(42.2)1(Reference)65(36.1)1(Reference)39(21.7)1(Reference)One episode167(43.8)1.04(0.41,2.62)0.946(37.5)1.04(0.39,2.77)0.943(18.7)0.87(0.24,3.12)0.83Relapsing7029(41.4)0.98(0.59,1.63)0.9425(35.7)0.99(0.58,1.69)0.9716(22.9)1.06(0.55,2.01)0.87Continuous9440(42.6)1.01(0.64,1.59)0.9734(36.2)1.00(0.62,1.63)0.9920(21.2)0.98(0.54,1.78)0.95Location18076(42.2)1(Reference)65(36.1)1(Reference)39(21.7)1(Reference)Proctitis (E1)7331(42.5)1.01(0.61,1.66)0.9826(35.6)0.99(0.58,1.68)0.9616(21.9)1.01(0.53,1.92)0.97Left side (E2)6426(40.6)0.96(0.57,1.63)0.8924(37.5)1.04(0.60,1.80)0.8914(21.9)1.01(0.52,1.98)0.98Extensive (E3)4319(44.2)1.05(0.57,1.91)0.8815(34.9)0.97(0.50,1.86)0.929(20.9)0.97(0.44,2.15)0.93Disease severity18076(42.2)1(Reference)65(36.1)1(Reference)39(21.7)1(Reference)Mild7633(43.4)1.03(0.63,1.68)0.9127(35.5)0.98(0.58,1.66)0.9516(21.1)0.97(0.51,1.84)0.93Moderate9539(41.1)0.97(0.61,1.54)0.9135(36.8)1.02(0.63,1.65)0.9421(22.1)1.02(0.57,1.83)0.95Severe94(44.5)1.05(0.32,3.52)0.933(33.3)0.92(0.24,3.52)0.912(22.2)1.03(0.21,4.93)0.98

Discussion {#Sec11}
==========

Recently, many studies have identified many SNPs associated with UC. A case--control study in 139 and 176 patients with UC and controls found that polymorphisms in *CD14* −159 C/T and *TLR4* −299 A/G significantly affected mCD14 and mTLR4 expression levels and also increased susceptibility to UC \[[@CR27]\]. A case--control study in a Korean population suggested that the −1920 G \> A polymorphism in *IFITM1* may be associated with susceptibility to UC (*P* = 0.002) \[[@CR28]\]. A case--control study in a group of 198 Mexican Mestizo patients with UC and 698 ethnically matched healthy unrelated individuals with no family history of UC suggested that the GG genotypes of the *IL-20* polymorphisms (rs2981573 and rs2232360) might have an important role in the development of UC (*P* = 0.017) in the Mexican population \[[@CR29]\]. A case--control study in 56 patients with UC and 50 healthy controls suggested that the *IL-10* −819 CC was a candidate genotype for both IBS (*P* = 0.047) and UC (*P* = 0.007) in Japanese \[[@CR30]\]. A case--control study suggested that the −1850 G/C polymorphism in the embryonic ectoderm development (*EED*) gene might be associated with the susceptibility to UC (*P* = 0.018) by the change of the *EED* expression level \[[@CR31]\]. A meta-analysis of seventeen studies with 18,308 cases and 20,406 controls indicated that the *PTPN2* polymorphism (rs2542151) was associated with increased UC risk \[[@CR32]\]. A meta-analysis of nine studies indicated that the vitamin D receptor (*VDR*) polymorphisms were associated with increased UC risk \[[@CR33]\]. A meta-analysis suggested that the migration inhibitory factor (*MIF*) gene −173 G/C polymorphism contributed to the susceptibility of UC \[[@CR34]\]. A case--control study included 422 very-early-onset IBD subjects and 480 healthy subjects suggested that *IL-10R* polymorphisms were associated with very-early-onset ulcerative colitis (*P* = 0.0002) \[[@CR35]\]. A case--control study included 171 UC and 213 healthy controls found that polymorphisms in *XRCC1* Arg399Gln and *APE1* Asp148Glu significantly increased the rate of apoptosis and risk of UC (*P* = 0.0007) \[[@CR36]\]. A case--control study in a group of 200 Mexican patients with UC and 248 ethnically matched unrelated healthy controls suggested that *IL-1 RN* and *IL-1B* polymorphisms were associated with the genetic susceptibility to develop UC and might be associated with the presence of steroid-dependence in UC patients (*P* = 0.019) \[[@CR37]\]. A case--control study in a group of 200 Mexican Mestizo patients with UC and 698 healthy unrelated individuals with no family history of UC suggested that *IL-19* polymorphisms (rs2243188 and rs2243193) might have a protective role in the development of UC (*P* = 0.018 and *P* = 0.006, respectively) in Mexican individuals \[[@CR38]\].

*IL-22* expression was involved in several human inflammatory conditions and autoimmune diseases. A study included 631 HCV patients found that *IL-22* polymorphisms were involved in the progression of persistent hepatitis C virus infection \[[@CR15]\]. A case--control study in 206 cases and 196 controls suggested that Polymorphisms in the *IL-22* receptor alpha-1 gene were associated with severe chronic rhinosinusitis (*P* = 0.0014) \[[@CR16]\]. A case--control study in 194 patients and 287 normal controls suggested that polymorphism of *IL-22* receptor alpha-1 was associated with the development of childhood IgA nephropathy (*P* = 0.002) \[[@CR22]\]. *IL-22* deficiency may contribute to the pathogenesis of certain chronic disorders as postulated in this paper for acne inversa \[[@CR39]\]. A study included 94 patients with COPD, 23 healthy smokers, and 22 healthy control non-smokers found that the increased sputum *IL-22* might also play important roles in the pathogenesis of chronic obstructive pulmonary disease (*P*\< 0.01) \[[@CR40]\]. A case--control study indicated that there was an increased expression level of *IL-22* and *IL-23* in patients with peri-implantitis (*P*\< 0.05) \[[@CR41]\]. A study in 18 cases and 21 controls suggested that increased expression of *IL-22* was associated with disease activity in Behcet's disease \[[@CR42]\]. *IL-22* has been reported to be involved in systemic sclerosis lesions \[[@CR43]\]. A study included allergic asthma (n = 18), controlled asthma (n = 17) and healthy controls (n = 12) found that *IL-22* might be involved in the pathogenesis of allergic asthma in human and the level of *IL-22* might have some relationship with the severity of the disease (*P*\< 0.05) \[[@CR44]\].

Our results should be taken with caution for some limitations. First of all, the numbers of subjects included in this study were small, and may not have been sufficient to reveal the associations between the *IL-22* gene polymorphisms (−429 C/T, +1046 T/A and +1995 A/C) and the risk of UC. Secondly, our investigation was not based on genome wide screening, but UC was induced by multiple genes and environmental factors, which were not explored in the present study. Thirdly, the participants in our research are only from Han Chinese ethnic group. It would be interesting to conduct similar studies in different populations for comparison. Finally, this is a hospital based case control study, so the selection bias cannot be avoidable and the subjects may not be representative of the general population.

Conclusions {#Sec12}
===========

In conclusion, this study provides evidence for an association of *IL-22* −429 C/T gene polymorphisms with UC risk. To the best of our knowledge this is the first study to provide evidence about the role of *IL-22* polymorphisms in the development of UC. Additional well-designed large-scale multicenter studies were required for the validation of our results.
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